No benefit of combining custirsen with cabazitaxel
نویسندگان
چکیده
منابع مشابه
Combining Neuroprotectants in a Model of Retinal Degeneration: No Additive Benefit
The central nervous system undergoing degeneration can be stabilized, and in some models can be restored to function, by neuroprotective treatments. Photobiomodulation (PBM) and dietary saffron are distinctive as neuroprotectants in that they upregulate protective mechanisms, without causing measurable tissue damage. This study reports a first attempt to combine the actions of PBM and saffron. ...
متن کاملTRIOLOGY ACS: No benefit/No harm
INTRODUCTION Potent and consistent P2Y12 receptor inhibition is associated with reduced risk of atherothrombotic events in patients presenting with acute coronary syndromes (ACS), but with inevitable increased risk of bleeding as demonstrated in TRITON and PLATO trials – a finding that is especially pertinent to the treatment of medically managed NSTE ACS patients, who typical have a greater bu...
متن کاملCabazitaxel (Jevtana)
440 P&T® • August 2012 • Vol. 37 No. 8 ABSTRACT Objective: This article presents current clinical evidence supporting the use of cabazitaxel (Jevtana) in men with metastatic castration-resistant prostate cancer (mCRPC). Data Sources: We conducted a literature search using abstracts from MEDLINE and PubMed (from January 1966 to December 2011) and the American Society of Clinical Oncology (from J...
متن کاملNo benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
OBJECTIVE About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable. METHODS We compared the new commercially available tumor marker HE4 with CA125 individually, in combination, within the ...
متن کاملPreclinical profile of cabazitaxel
First-generation taxanes have changed the treatment paradigm for a wide variety of cancers, but innate or acquired resistance frequently limits their use. Cabazitaxel is a novel second-generation taxane developed to overcome such resistance. In vitro, cabazitaxel showed similar antiproliferative activity to docetaxel in taxane-sensitive cell lines and markedly greater activity in cell lines res...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Urology
سال: 2017
ISSN: 1759-4812,1759-4820
DOI: 10.1038/nrurol.2017.193